RA0762

antibody from Oursmab

Targeting: TNFRSF4 ACT35, CD134, OX40, TXGP1L

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0762

Provider

Oursmab

Product name

Ivuxolimab (Biosimilar Reference Antibody) (TNFRSF4)

Antibody type

Monoclonal

Description

Ivuxolimab is a humanized IgG2 monoclonal antibody agonist targeting OX40 (CD134). Its IgG2 isotype is selected to minimize antibody-dependent effector functions while maximizing the agonistic activity required to directly stimulate the OX40 receptor. By binding to OX40 on activated T cells, Ivuxolimab is designed to enhance T-cell proliferation, survival, and functional activity, thereby promoting a robust anti-tumor immune response. It has been developed and investigated as an immune stimulatory therapy for various advanced solid tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.